Tumor Volume and Calcifications As Indicators for Preoperative Differentiation of Grade II/III Diffuse Gliomas

Overview

Journal J Neurooncol

Publisher Springer

Date 2023 Feb 7

PMID 36749444

Authors

Yasukazu Fukuya

Manabu Tamura

Masayuki Nitta

Taiichi Saito

Shunsuke Tsuzuki

Shunichi Koriyama

Atsushi Kuwano

Takakazu Kawamata

Yoshihiro Muragaki

Affiliations

Soon will be listed here.

Abstract

Purpose: To retrospectively evaluate preoperative clinical factors for their ability to preoperatively differentiate malignancy grades in patients with incipient supratentorial grade II/III diffuse gliomas.

Methods: This retrospective study included 206 adult patients with incipient supratentorial grade II/III diffuse gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. The cohort included 136 men and 70 women, with a median age of 41 years. Preoperative factors included age, sex, presence of calcifications on computed tomography scans, and preoperative tumor volume measured using preoperative magnetic resonance imaging.

Results: In patients with oligodendrogliomas (IDH-mutant and 1p/19q-codeleted), calcifications were significantly more frequent (p = 0.0034) and tumor volume was significantly larger (p < 0.001) in patients with grade III tumors than in those with grade II tumors. Moreover, in patients with IDH-mutant astrocytomas, preoperative tumor volume was significantly larger (p = 0.0042) in patients with grade III tumors than in those with grade II tumors. In contrast, none of the evaluated preoperative clinical factors were significantly different between the patients with grade II and III IDH-wildtype astrocytomas.

Conclusion: In adult patients with suspicison incipient supratentorial grade II/III diffuse gliomas, presence of calcifications and larger preoperative tumor volume might be used as preoperative indices to differentiate between malignancy grades II and III in oligodendrogliomas (IDH-mutant and 1p/19q-codeleted) and larger preoperative tumor volume might have similar utility in IDH-mutant astrocytomas.

Citing Articles

Revisiting oligodendroglioma grading in the 2021 WHO classification: calcification and larger contrast-enhancing tumor volume may predict higher oligodendroglioma grade.

Lee D, Choi K, Han K, Choi S, Lee N, Ahn S Neuroradiology. 2024; 66(9):1527-1535.

PMID: 39014271 DOI: 10.1007/s00234-024-03430-y.

Accuracy of MRI in Detecting 1p/19q Co-deletion Status of Gliomas: A Single-Center Retrospective Study.

Naeem A, Aziz N, Nasir M, Rangwala H, Fatima H, Mubarak F Cureus. 2024; 16(1):e51863.

PMID: 38327950 PMC: 10848880. DOI: 10.7759/cureus.51863.

Intratumoral calcification seems like the tree rings for tumours such as oligodendroglioma.

Dong F, Li Q Eur Radiol. 2023; 34(6):3671-3673.

PMID: 38108889 DOI: 10.1007/s00330-023-10508-3.

References

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

Kleihues P, Louis D, Scheithauer B, Rorke L, Reifenberger G, Burger P . The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61(3):215-25; discussion 226-9. DOI: 10.1093/jnen/61.3.215. View

Kilic T, Ozduman K, Elmaci I, Sav A, Pamir M . Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas. J Clin Neurosci. 2002; 9(5):549-52. DOI: 10.1054/jocn.2002.1136. View

Jaeckle K, Decker P, Ballman K, Flynn P, Giannini C, Scheithauer B . Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol. 2010; 104(1):253-9. PMC: 5738240. DOI: 10.1007/s11060-010-0476-2. View

Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D . Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res. 2007; 13(5):1429-37. DOI: 10.1158/1078-0432.CCR-06-2050. View

Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A . Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status. Brain Tumor Pathol. 2012; 29(4):183-91. DOI: 10.1007/s10014-012-0113-1. View

Schmidt M, Berger M, Lamborn K, Aldape K, McDermott M, Prados M . Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg. 2003; 98(6):1165-9. DOI: 10.3171/jns.2003.98.6.1165. View

10.

Fukuya Y, Ikuta S, Maruyama T, Nitta M, Saito T, Tsuzuki S . Tumor recurrence patterns after surgical resection of intracranial low-grade gliomas. J Neurooncol. 2019; 144(3):519-528. DOI: 10.1007/s11060-019-03250-8. View

11.

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2012; 31(3):337-43. PMC: 3732012. DOI: 10.1200/JCO.2012.43.2674. View

12.

van den Bent M, Brandes A, Taphoorn M, Kros J, Kouwenhoven M, Delattre J . Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2012; 31(3):344-50. DOI: 10.1200/JCO.2012.43.2229. View

13.

van den Bent M, Afra D, De Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K . Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005; 366(9490):985-90. DOI: 10.1016/S0140-6736(05)67070-5. View

14.

Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P . Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002; 20(8):2076-84. DOI: 10.1200/JCO.2002.08.121. View

15.

Chang E, Smith J, Chang S, Lamborn K, Prados M, Butowski N . Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008; 109(5):817-24. DOI: 10.3171/JNS/2008/109/11/0817. View

16.

Nitta M, Muragaki Y, Maruyama T, Ikuta S, Komori T, Maebayashi K . Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. Neurosurg Focus. 2015; 38(1):E7. DOI: 10.3171/2014.10.FOCUS14651. View

17.

Rossi M, Gay L, Ambrogi F, Conti Nibali M, Sciortino T, Puglisi G . Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Neuro Oncol. 2020; 23(5):812-826. PMC: 8099476. DOI: 10.1093/neuonc/noaa225. View

18.

van den Bent M, Wefel J, Schiff D, Taphoorn M, Jaeckle K, Junck L . Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011; 12(6):583-93. DOI: 10.1016/S1470-2045(11)70057-2. View

19.

Ellika S, Jain R, Patel S, Scarpace L, Schultz L, Rock J . Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. AJNR Am J Neuroradiol. 2007; 28(10):1981-7. PMC: 8134232. DOI: 10.3174/ajnr.A0688. View

20.

Ding B, Ling H, Chen K, Jiang H, Zhu Y . Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging. Neuroradiology. 2006; 48(10):773-81. DOI: 10.1007/s00234-006-0120-1. View